Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB006 in Outpatient Mild to Moderate COVID-19
NCT04801056Phase 1Withdrawn
- Sponsor
- TrueBinding Inc.
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing TB006 with Placebo (2 arms). Primary endpoint: Treatment emergent adverse events at Day 85. Planned start Jun 2021; status: withdrawn.
02
Drugs
TB006
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04801056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04801056.